Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 18/20 | 0.75 |
| ▸ | BCHE | P06276 | 17/20 | 0.75 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202137 | 1.00 | ACHE (0.75) | ACHEBCHEMAOBAPP | |
| SCHEMBL4200742 | 1.00 | ACHE (0.75) | ACHEBCHEMAOBAPP | |
| SCHEMBL4203482 | 0.99 | ACHE (0.72) | ACHEBCHEMAOBAPP | |
| SCHEMBL4363868 | 0.94 | ACHE (0.70) | ACHEBCHEMAOB | |
| SCHEMBL4367373 | 0.88 | ACHE (0.65) | ACHEBCHEMAOB | |
| SCHEMBL4543965 | 0.84 | ACHE (0.66) | ACHEBCHEMAOBAPP | |
| SCHEMBL5482410 | 0.84 | ACHE (0.76) | ACHEBCHE | |
| SCHEMBL13706589 | 0.83 | ACHE (0.77) | ACHEBCHEMAOBAPP | |
| SCHEMBL13706633 | 0.82 | CHRM2 (0.82) | ACHEBCHEMAOBAPP | |
| SCHEMBL4371900 | 0.82 | ACHE (0.66) | ACHEBCHEMAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | PSEN2, BACE2, WEE2 | ACHE 169/4885BCHE 77/4885MAOB 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.